HHT
9
2
5
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.4% vs benchmark
11%
1 trials in Phase 3/4
25%
1 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (9)
Bevacizumab in the Treatment of HHT
CHORUS - Comprehensive HHT Outcomes Registry of the United States (Formerly OUR HHT Registry)
Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz)
Institutional Registry of Rare Diseases
Genotype-phenotype Association in Hereditary Hemorrhagic Telangiectasia
Tourniquet-Test in HHT
Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH
Intranasal Bevacizumab for HHT-Related Epistaxis
Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)